Psychedelic Institute of Mental Health & Family Therapy
Psychedelic Institute of Mental Health & Family Therapy
Telehealth Ketamine Therapists
⌘K
Contact
Psychedelic Institute of Mental Health & Family Therapy
ketamine

Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)

"...the real-world clinical data presented here suggest a sustained effectiveness and safety profile of longer-term ketamine treatment for up to 6 months for patients with TRD. "
Michael DeMarco, PhD

by Michael DeMarco, PhD

Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)
Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)
Datos clínicos del mundo real sobre la eficacia y la seguridad a largo plazo del tratamiento genérico de la ketamina racemica (Massaneda-Tuneu, et al, 2025) Aspectos destacados - La mayoría de las personas con DPR en nuestra muestra parecía experimentar una respuesta sostenida al tratamiento con 2-6 meses de ketamina racemica genérica. - No se observaron resultados adversos graves y la tolerabilidad general fue buena. - Nuestros hallazgos sugieren que implementar un marco estructurado de monitoreo de la seguridad es importante en la práctica clínica rutinaria para la evaluación y gestión de la seguridad del tratamiento.

Datos clínicos del mundo real sobre la eficacia y la seguridad a largo plazo del tratamiento genérico de la ketamina racemica (Massaneda-Tuneu, et al, 2025)

"los datos clínicos del mundo real presentados aquí sugieren una eficacia y un perfil de seguridad sostenidos del tratamiento de la ketamina a más largo plazo durante un máximo de 6 meses para pacientes con DPR."

More like this

Spotlight: The Effectiveness of Combining Ketamine and Cognitive Behavioural Therapy in Treating Major Depressive Disorder (2025)

" This study seeks to investigate the combined effectiveness of ketamine and CBT in the treatment of MDD, with the hypothesis that integrated treatment will outperform either modality administered alone."

Spotlight: "Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition (Oughli, et al, 2023)

"This pilot study suggests that repeated IV ketamine infusions are well-tolerated and are associated with improvement in depression and EF in older adults with TRD."

Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology (Wittenkeller, et al, 2025)

"enhancing baseline dopamine while minimising excessive drug-induced dopamine surges may help normalise motivational circuits and reduce relapse risk."

Spotlight: Toward Consensus in Psychedelic-Assisted Therapy: The Critical Role of Psychotherapeutic Support (Modesto-Lowe, et al, 2025)

"...psychotherapy is essential for the safety and efficacy of psychedelic-assisted therapy... Insight from naturalistic settings emphasizes the importance of group dynamics and context."

Spotlight: MDMA + Psychotherapy as a treatment for major depressive disorder: proof of principle study (Kvam, et al, 2025)

"There were no adverse events of special interest, and no unexpected or serious adverse events. The study met the primary objectives of safety and feasibility, and provided indications of efficacy for MDMA-AT for MDD. Further studies with a randomised design are required to confirm these findings."

Spotlight: From Anesthetic to Neuroprotector: Multi-Omics Reveals Ketamine's Previously Unexplored Neuroprotective Role in Alzheimer's Disease (Gong, et al, 2025)

"This integrative study identifies robust diagnostic biomarkers and nominates ketamine for repurposing in AD. Experimental validation of ketamine's neuroprotective effects and FIBP's role is warranted."
Mastodon Mastodon